CaroGen Corporation Revenue and Competitors
Estimated Revenue & Valuation
- CaroGen Corporation's estimated annual revenue is currently $1.9M per year.
- CaroGen Corporation's estimated revenue per employee is $155,000
Employee Data
- CaroGen Corporation has 12 Employees.
- CaroGen Corporation grew their employee count by -8% last year.
CaroGen Corporation's People
| Name | Title | Email/Phone |
|---|---|---|
1 | President & CEO | Reveal Email/Phone |
2 | Co-Founder, Chief Scientific Officer, Sr. VP | Reveal Email/Phone |
3 | Chief Medical Officer | Reveal Email/Phone |
4 | VP, Discovery | Reveal Email/Phone |
5 | Global VP, Business Development | Reveal Email/Phone |
6 | Global VP, Business Development | Reveal Email/Phone |
7 | VP, Product Development | Reveal Email/Phone |
8 | VP, Strategy & Finance | Reveal Email/Phone |
9 | Principal Scientist | Reveal Email/Phone |
10 | Scientific Researcher | Reveal Email/Phone |
CaroGen Corporation Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $0.2M | 1 | -80% | N/A | N/A |
#2 | $4.3M | 28 | 8% | N/A | N/A |
#3 | $9.8M | 66 | -11% | N/A | N/A |
#4 | $1.4M | 9 | 350% | N/A | N/A |
#5 | $16.6M | 107 | -23% | N/A | N/A |
#6 | $4.5M | 29 | -22% | N/A | N/A |
#7 | $1.7M | 11 | 57% | N/A | N/A |
#8 | $2.3M | 15 | -6% | N/A | N/A |
#9 | $0.3M | 4 | -43% | N/A | N/A |
#10 | $4M | 26 | 0% | N/A | N/A |
What Is CaroGen Corporation?
CaroGen Corporation is an emerging biopharmaceutical company with an entirely new vaccine platform technology developed at Yale University School of Medicine. The Company has recently executed an exclusive license with Yale University to the replication proficient virus-like vesicle (VLV) a platform technology for the development of vaccines for worldwide commercialization. The proprietary VLV technology which has been validated in a number of animal models including non-human primates will be employed to create new, potentially first-in-class vaccines that engage the body’s immune system to both recognize and fight off various diseases. Our vision is to control the spread of infectious diseases by using viral-based technology to produce recombinant protein nanoparticle vaccines for viruses, bacteria and parasites. We are dedicated to creating recombinant vaccines to address a broad range of infectious and chronic diseases. The company is developing a portfolio of vaccine candidates targeting hepatitis B virus, and potentially hepatitis C and other viral agents.
keywords:N/A
N/A
Total Funding
12
Number of Employees
$1.9M
Revenue (est)
-8%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Farmington
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $2.1M | 12 | 50% | N/A |
#2 | $2M | 13 | -35% | N/A |
#3 | $2.4M | 14 | -55% | N/A |
#4 | N/A | 14 | -52% | N/A |
#5 | $1.9M | 16 | N/A | N/A |